½ÃÀ庸°í¼­
»óǰÄÚµå
1665346

¸·Çü »ê¼Ò°ø±Þ±â ½ÃÀå ±âȸ¿Í ÃËÁø¿äÀÎ, ¾÷°è µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)

Membrane Oxygenators Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 140 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

2024³â 1¾ï 3,210¸¸ ´Þ·¯·Î Æò°¡µÈ ¼¼°è ¸âºê·¹ÀÎ »ê¼Ò°ø±Þ±â ½ÃÀåÀº 2025-2034³â°£ 2.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ²ÙÁØÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº ±Þ¼º È£Èí°ï¶õ ÁõÈıº(ARDS), ½ÉÀμº ¼îÅ©, ½É±Ù¿°°ú °°Àº È£Èí±â ¹× ½ÉÀå ÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ÷´Ü »ê¼Ò °ø±Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸âºê·¹ÀÎ »ê¼Ò ÈíÀÔ±â´Â »ý¸í À¯Áö, ƯÈ÷ ÁßȯÀڽǿ¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ Áúȯ¿¡ °É¸®±â ½¬¿î ¼¼°è Àα¸ÀÇ °í·ÉÈ­´Â ½ÃÀå È®´ë¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Áß°ø »ç¸·°ú °°Àº ±â¼ú Çõ½ÅÀº °¡½º ±³È¯ È¿À²À» Çâ»ó½ÃÄÑ ÀÇ·á ÇöÀå¿¡¼­ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Membrane Oxygenators Market-IMG1

À¯Çüº°·Î´Â Áß°ø»ç¸·Çü »ê¼Ò ÈíÀԱⰡ °í¼ºÀå ºÎ¹®À¸·Î µÎµå·¯Áö¸ç, CAGR 2.6%·Î ¼ºÀåÇÏ¿© 2034³â±îÁö 1¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¡½º ±³È¯ È¿À²¼º°ú ÄÄÆÑÆ®ÇÑ µðÀÚÀÎÀ¸·Î Àß ¾Ë·ÁÁø ÀÌ »ê¼Ò °ø±Þ±â´Â ƯÈ÷ ÀÀ±Þ»óȲ¿¡¼­ ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ½Ã¼ú¿¡ ÀûÇÕÇÕ´Ï´Ù. ¼ºÀÎ ¹× ¼Ò¾Æ ÀÇ·á ȯ°æ¿¡¼­ »ç¿ëÇÒ ¼ö ÀÖ¾î ½ÃÀå Áö¹è·ÂÀ» È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 1¾ï 3,210¸¸ ´Þ·¯
¿¹»ó ±Ý¾× 1¾ï 6,280¸¸ ´Þ·¯
CAGR 2.2%

¿ëµµº°·Î´Â È£Èí±â ºÎ¹®ÀÌ 2034³â±îÁö ¿¬Æò±Õ 1.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 7,250¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, È£Èí±â ºÎ¹®ÀÌ °è¼ÓÇØ¼­ Å« ÀáÀç·ÂÀ» º¸¿©ÁÙ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) ¹× Æó·Å°ú °°Àº È£Èí±â ÁúȯÀÇ ¹ßº´·ü Áõ°¡°¡ ÁÖ¿ä ¼ö¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. °í·ÉÈ­, ´ë±â¿À¿° Áõ°¡, ´ã¹èÀÇ º¸±Þ µîÀÇ ¿äÀÎÀÌ Àü ¼¼°èÀûÀ¸·Î È£Èí±â ÇÕº´Áõ Áõ°¡¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¡Å©¸ð ¿ä¹ý ¹× ¸·Çü »ê¼Ò ³óÃà±âÀÇ Çʿ伺À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ ¸âºê·¹ÀÎ »ê¼Ò°ø±Þ±â ½ÃÀåÀº 2024³â 4,420¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç 2034³â±îÁö ¿¬Æò±Õ 1.4% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ³ª¶óÀÇ ÅºÅºÇÑ ÀÇ·á ÀÎÇÁ¶ó¿Í È£Èí±â ¹× ½ÉÇ÷°ü ÁúȯÀÇ ³ôÀº À¯º´·üÀÌ ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ¿¡ °É¸®±â ½¬¿î °í·ÉÈ­ »çȸ´Â ¿¡Å©¸ð Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ½Å»ý¾Æ ¹× ¼Ò¾Æ ÀÇ·á ºÐ¾ß¿¡¼­ ÷´Ü »ý¸í À¯Áö ½Ã½ºÅÛÀÇ Ã¤Åà Áõ°¡¿Í ÇÔ²² ÈÞ´ë¿ë °í¼º´É »ê¼Ò °ø±Þ ÀåÄ¡ÀÇ ±â¼ú Çõ½ÅÀº ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¶Ç ´Ù¸¥ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • »ê¾÷¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • »ê¾÷ÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼ú »óȲ
  • °¸ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • ü¿Ü½Ä¸·Çü »ê¼Ò°ø±Þ±â(ECMO) ÁøÈ­
  • ECMO·Î Áö¿ø µÇ´Â ȯÀÚ AI¿¡ ÀÇÇÑ ÃâÇ÷ ¿¹Ãø

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : À¯Çüº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • Hollow fiber
  • Flat sheet

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿ëµµº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • È£Èí±â
    • È£Èí ºÎÀü
    • Æó»öÀüÁõ
    • ±Þ¼º È£Èí°ï¶õ ÁõÈıº
    • Æó·Å
    • COVID-19
  • ½ÉÀå
    • ´ë»ó¼º ½É±ÙÁõ
    • ±Þ¼º ½É±Ù°æ»ö
    • ½É¿ø¼º ¼îÅ©
    • À̽ÄÈÄ ÇÕº´Áõ
    • ½É±Ù¿°
  • ü¿Ü ½ÉÆó ¼Ò»ý¹ý

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¿¬·ÉÃþº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ¼ºÀÎ
  • ½Å»ý¾Æ
  • ¼Ò¾Æ

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦9Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2034³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)

Á¦10Àå ±â¾÷ °³¿ä

  • Abbott
  • BRAILE
  • chalice
  • CytoSorbents
  • EUROSETS
  • Fresenius
  • GETINGE
  • LivaNova
  • Medtronic
  • MicroPort
  • NIPRO
  • PrecisionMedical
  • RECTUS MEDICAl
  • TERUMO
  • XENIOS
LSH 25.03.12

The Global Membrane Oxygenators Market, valued at USD 132.1 million in 2024, is poised for steady growth with a projected CAGR of 2.2% between 2025 and 2034. This growth is driven by the rising prevalence of respiratory and cardiac disorders, including acute respiratory distress syndrome (ARDS), cardiogenic shock, and myocarditis, which are fueling demand for advanced oxygenation systems. Membrane oxygenators play a vital role in life support, especially in critical care scenarios. Additionally, the aging global population, which is more vulnerable to these conditions, further accelerates market expansion. Technological innovations, such as the adoption of hollow fiber membranes, are enhancing gas exchange efficiency and boosting adoption across healthcare settings.

Membrane Oxygenators Market - IMG1

By type, hollow fiber membrane oxygenators stand out as a high-growth segment. Expected to grow at a CAGR of 2.6%, this segment is anticipated to generate USD 100.6 million by 2034. Known for their efficiency in gas exchange and compact design, these oxygenators are particularly suited for extracorporeal membrane oxygenation (ECMO) procedures in emergency situations. Their adaptability for use in both adult and pediatric care settings cements their market dominance.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$132.1 Million
Forecast Value$162.8 Million
CAGR2.2%

In terms of application, the respiratory segment continues to demonstrate strong potential, projected to reach USD 72.5 million by 2034 with a CAGR of 1.9%. The increasing incidence of respiratory conditions such as chronic obstructive pulmonary disease (COPD) and pneumonia is a key driver of demand. Factors like aging populations, escalating air pollution levels, and widespread tobacco use are contributing to a global rise in respiratory complications, heightening the need for ECMO therapy and membrane oxygenators.

The U.S. membrane oxygenators market, valued at USD 44.2 million in 2024, is expected to grow at a CAGR of 1.4% through 2034. The country's robust healthcare infrastructure and high prevalence of respiratory and cardiovascular diseases make it a significant contributor to market expansion. An aging population prone to chronic health conditions further bolsters demand for ECMO treatments. Innovations in portable and high-performance oxygenators, coupled with increasing adoption of advanced life-support systems in neonatal and pediatric care, are additional factors driving regional growth.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising cardiovascular disease prevalence
      • 3.2.1.2 Growing demand for extracorporeal membrane oxygenation (ECMO)
      • 3.2.1.3 High incidence of acute respiratory distress syndrome (ARDS)
      • 3.2.1.4 Rise in organ transplant procedures
      • 3.2.1.5 Surging application in pediatric and neonatal care
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Strict regulatory requirements
      • 3.2.2.2 High costs of advanced oxygenators
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Gap analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
  • 3.10 Value chain analysis
  • 3.11 Evolution of extracorporeal membrane oxygenators (ECMO)
  • 3.12 AI-enabled prediction of bleeding in patients supported on ECMO

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 — 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Hollow fiber membrane oxygenators
  • 5.3 Flat sheet membrane oxygenators

Chapter 6 Market Estimates and Forecast, By Application, 2021 — 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Respiratory
    • 6.2.1 Respiratory failure
    • 6.2.2 Pulmonary embolism
    • 6.2.3 Acute respiratory distress syndrome
    • 6.2.4 Pneumonia
    • 6.2.5 COVID-19
  • 6.3 Cardiac
    • 6.3.1 Decompensated cardiomyopathy
    • 6.3.2 Acute myocardial infarction
    • 6.3.3 Cardiogenic shock
    • 6.3.4 Post-transplant complications
    • 6.3.5 Myocarditis
  • 6.4 Extra corporeal cardiopulmonary resuscitation

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 — 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adults
  • 7.3 Neonates
  • 7.4 Pediatrics

Chapter 8 Market Estimates and Forecast, By End Use, 2021 — 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Ambulatory surgical centers
  • 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 — 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott
  • 10.2 BRAILE
  • 10.3 chalice
  • 10.4 CytoSorbents
  • 10.5 EUROSETS
  • 10.6 Fresenius
  • 10.7 GETINGE
  • 10.8 LivaNova
  • 10.9 Medtronic
  • 10.10 MicroPort
  • 10.11 NIPRO
  • 10.12 PrecisionMedical
  • 10.13 RECTUS MEDICAl
  • 10.14 TERUMO
  • 10.15 XENIOS
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦